InvestorsHub Logo
Followers 0
Posts 37
Boards Moderated 0
Alias Born 10/16/2013

Re: None

Wednesday, 10/22/2014 11:42:32 AM

Wednesday, October 22, 2014 11:42:32 AM

Post# of 1914
Great data presented by RGLS. Stock up >100% and ROSG is down. miR's certainly have a promising future!

Regulus Therapeutics announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122, for the treatment of hepatitis C virus infection